Kite development head Ken Takeshita jumps to Daiichi Sankyo amid oncology push
Months after leading Kite Pharma to a landmark OK and establishing the first-ever commercial CAR-T portfolio, global development head Ken Takeshita vaguely announced he was leaving the helm for another opportunity. Now we know what he’s been up to.
Takeshita is jumping over to Daiichi Sankyo on April 1, where he’ll lead the company’s push to become an established oncology player as global head of R&D. He’s filling the shoes of Junichi Koga, who’s retiring after 12 years at the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.